BR112015014010A2 - peptídeos como agonistas oxitocina - Google Patents
peptídeos como agonistas oxitocinaInfo
- Publication number
- BR112015014010A2 BR112015014010A2 BR112015014010A BR112015014010A BR112015014010A2 BR 112015014010 A2 BR112015014010 A2 BR 112015014010A2 BR 112015014010 A BR112015014010 A BR 112015014010A BR 112015014010 A BR112015014010 A BR 112015014010A BR 112015014010 A2 BR112015014010 A2 BR 112015014010A2
- Authority
- BR
- Brazil
- Prior art keywords
- lower alkyl
- hydrogen
- hydroxy
- cycloalkyl
- heterocyclic group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
resumo patente de invenção: "peptídeos como agonistas oxitocina". a invenção refere-se aos compostos de fórmula i em que r1 é hidróxi ou amino; r2 é sec-butila ou isobutila; r3 é alquila inferior, alquila inferior substituída por hidróxi, grupo heterocíclico aromático de cinco membros -(ch2)2c(o)-nh2, -(ch2)3-nh2 ou -ch2; r4 é hidrogênio ou alquila inferior; r5 é hidrogênio ou alquila inferior; ou r4 e r5 podem formar juntos com o átomo de n e c ao qual eles são ligados um anel de pirrolidina, opcionalmente substituída por hidróxi ou halogênio, um anel piperidina ou um anel azetidina; r6 é hidrogênio, alquila inferior, alquila inferior substituída por hidróxi, -(ch2)2c(o)oh, -(ch2)2c(o)nh2, benzila opcionalmente substituída por amino ou hidróxi, grupo heterocíclico aromático de cinco membros -ch2, indolila, -ch2-cicloalquila, cicloalquila, alquila -(ch2)2-s-inferior ou é -(ch2)1-4-nh2; r6' é hidrogênio ou alquila inferior; ou r6 e r6' são juntamente cicloalquila; xé -c(o)-chr-nr'-c(o)-; r/r' são independentemente um do outro hidrogênio ou alquila inferior; m é 2; o é 0 ou 1; ou a um sal de adição ácido farmaceuticamente aceitável, a uma mistura racêmica ou a seu enantiômero correspondente e/ou isômeros ópticos dos mesmos. eles são agonistas do receptor de oxitocina para o tratamento de autismo, estresse, incluindo distúrbio de estresse pós-traumático, ansiedade, incluindo distúrbios de ansiedade e depressão, esquizofrenia, distúrbios psiquiátrico e perda de memória, abstinência de álcool, dependência de droga e para o tratamento de síndrome de prader-willi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12199012 | 2012-12-21 | ||
PCT/EP2013/076783 WO2014095773A1 (en) | 2012-12-21 | 2013-12-17 | Peptides as oxytocin agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015014010A2 true BR112015014010A2 (pt) | 2017-07-11 |
Family
ID=47471593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015014010A BR112015014010A2 (pt) | 2012-12-21 | 2013-12-17 | peptídeos como agonistas oxitocina |
Country Status (34)
Country | Link |
---|---|
US (1) | US9868766B2 (pt) |
EP (1) | EP2935312B1 (pt) |
JP (1) | JP6067878B2 (pt) |
KR (1) | KR101819804B1 (pt) |
CN (1) | CN104870466B (pt) |
AR (1) | AR094225A1 (pt) |
AU (1) | AU2013363768B2 (pt) |
BR (1) | BR112015014010A2 (pt) |
CA (1) | CA2895150C (pt) |
CL (1) | CL2015001724A1 (pt) |
CR (1) | CR20150271A (pt) |
DK (1) | DK2935312T3 (pt) |
EA (1) | EA026687B1 (pt) |
ES (1) | ES2690317T3 (pt) |
HK (1) | HK1208477A1 (pt) |
HR (1) | HRP20181569T1 (pt) |
HU (1) | HUE039848T2 (pt) |
IL (1) | IL239519A (pt) |
LT (1) | LT2935312T (pt) |
MA (1) | MA38272A1 (pt) |
MX (1) | MX358684B (pt) |
MY (1) | MY176398A (pt) |
NZ (1) | NZ708175A (pt) |
PE (1) | PE20151446A1 (pt) |
PH (1) | PH12015501145B1 (pt) |
PL (1) | PL2935312T3 (pt) |
PT (1) | PT2935312T (pt) |
RS (1) | RS57690B1 (pt) |
SG (1) | SG11201504883PA (pt) |
SI (1) | SI2935312T1 (pt) |
TW (1) | TWI558726B (pt) |
UA (1) | UA119034C2 (pt) |
WO (1) | WO2014095773A1 (pt) |
ZA (1) | ZA201504186B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
KR101819804B1 (ko) | 2012-12-21 | 2018-01-17 | 에프. 호프만-라 로슈 아게 | 옥시토신 작용제로서의 펩타이드 |
EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
KR102116107B1 (ko) | 2013-12-30 | 2020-05-28 | 삼성디스플레이 주식회사 | 표시 장치 |
WO2015106200A2 (en) | 2014-01-10 | 2015-07-16 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
PE20161559A1 (es) | 2014-06-03 | 2017-01-12 | Hoffmann La Roche | Peptidos como agonistas de la oxitocina |
AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
TR201815872T4 (tr) * | 2014-08-07 | 2018-11-21 | Hoffmann La Roche | Oksitosin analoglarının hazırlanması için prosesler. |
WO2016028571A2 (en) * | 2014-08-18 | 2016-02-25 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
US10441627B2 (en) | 2014-09-19 | 2019-10-15 | Ferring B.V. | Method of treating prader-willi syndrome |
EP3362754B1 (en) | 2015-10-15 | 2021-12-22 | Cornell University | Proteasome inhibitors and uses thereof |
EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC PROTEASOME INHIBITORS |
WO2020061414A1 (en) | 2018-09-20 | 2020-03-26 | Levo Therapeutics, Inc. | Stable intranasal formulations of carbetocin |
TW202034899A (zh) | 2018-09-20 | 2020-10-01 | 克里斯托弗 S 布萊恩特 | 卡貝縮宮素藥品及其製備方法 |
WO2021126990A1 (en) * | 2019-12-16 | 2021-06-24 | The Scripps Research Institute | Oxytocin derivatives with improved properties |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673841B2 (en) | 2008-03-31 | 2014-03-18 | Ferring B.V. | Oxytocin analogues |
TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
ES2509270T3 (es) * | 2009-10-01 | 2014-10-17 | The University Of Sydney | Terapia y prevención del alcoholismo |
KR101819804B1 (ko) | 2012-12-21 | 2018-01-17 | 에프. 호프만-라 로슈 아게 | 옥시토신 작용제로서의 펩타이드 |
-
2013
- 2013-12-17 KR KR1020157016376A patent/KR101819804B1/ko active IP Right Grant
- 2013-12-17 CN CN201380066617.7A patent/CN104870466B/zh not_active Expired - Fee Related
- 2013-12-17 WO PCT/EP2013/076783 patent/WO2014095773A1/en active Application Filing
- 2013-12-17 AU AU2013363768A patent/AU2013363768B2/en not_active Ceased
- 2013-12-17 MX MX2015007365A patent/MX358684B/es active IP Right Grant
- 2013-12-17 DK DK13814079.3T patent/DK2935312T3/en active
- 2013-12-17 PL PL13814079T patent/PL2935312T3/pl unknown
- 2013-12-17 ES ES13814079.3T patent/ES2690317T3/es active Active
- 2013-12-17 HU HUE13814079A patent/HUE039848T2/hu unknown
- 2013-12-17 RS RS20181124A patent/RS57690B1/sr unknown
- 2013-12-17 PE PE2015001058A patent/PE20151446A1/es unknown
- 2013-12-17 SI SI201331190T patent/SI2935312T1/sl unknown
- 2013-12-17 MA MA38272A patent/MA38272A1/fr unknown
- 2013-12-17 SG SG11201504883PA patent/SG11201504883PA/en unknown
- 2013-12-17 EP EP13814079.3A patent/EP2935312B1/en active Active
- 2013-12-17 JP JP2015548420A patent/JP6067878B2/ja not_active Expired - Fee Related
- 2013-12-17 BR BR112015014010A patent/BR112015014010A2/pt not_active IP Right Cessation
- 2013-12-17 CA CA2895150A patent/CA2895150C/en not_active Expired - Fee Related
- 2013-12-17 MY MYPI2015001585A patent/MY176398A/en unknown
- 2013-12-17 LT LTEP13814079.3T patent/LT2935312T/lt unknown
- 2013-12-17 UA UAA201506906A patent/UA119034C2/uk unknown
- 2013-12-17 NZ NZ708175A patent/NZ708175A/en not_active IP Right Cessation
- 2013-12-17 EA EA201591078A patent/EA026687B1/ru not_active IP Right Cessation
- 2013-12-17 PT PT13814079T patent/PT2935312T/pt unknown
- 2013-12-20 TW TW102147655A patent/TWI558726B/zh not_active IP Right Cessation
- 2013-12-20 AR ARP130104962A patent/AR094225A1/es unknown
-
2015
- 2015-05-21 CR CR20150271A patent/CR20150271A/es unknown
- 2015-05-22 PH PH12015501145A patent/PH12015501145B1/en unknown
- 2015-06-10 ZA ZA2015/04186A patent/ZA201504186B/en unknown
- 2015-06-18 US US14/743,009 patent/US9868766B2/en active Active
- 2015-06-18 CL CL2015001724A patent/CL2015001724A1/es unknown
- 2015-06-18 IL IL239519A patent/IL239519A/en active IP Right Grant
- 2015-09-18 HK HK15109189.5A patent/HK1208477A1/xx not_active IP Right Cessation
-
2018
- 2018-10-02 HR HRP20181569TT patent/HRP20181569T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015014010A2 (pt) | peptídeos como agonistas oxitocina | |
AU2016262729B2 (en) | S1P Modulating Agents | |
EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
MX370661B (es) | Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona. | |
RU2014145682A (ru) | Органические соединения | |
EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
ES2734734T3 (es) | Compuestos de amida como agonistas del receptor 5-HT4 | |
MX2015008830A (es) | Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central. | |
WO2013058681A3 (ru) | Замещенные феноксиуксусные кислоты их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент-антагонисты аденозинового а2а рецептора и их применение | |
PH12016502232A1 (en) | Peptides as oxytocin agonists | |
MX2012002256A (es) | Antagonistas carbociclicos de receptores de inhibidores de transportador de glicina 1 (glty1). | |
ECSP10010397A (es) | Preparacion y separacion enantiomerica de 7-(3- piridinilo)-1,7-diazaspiro[4.4] nonano y formas novedosas de sal de la mezcla racemica y enantiomeros | |
MX2011007272A (es) | Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1. | |
EA201270610A1 (ru) | Хинуклидиновые соединения как альфа-7 лиганды ацетилхолинового рецептора | |
WO2009148290A3 (en) | 3-substituted propanamine compounds | |
RU2437872C2 (ru) | Замещенные производные фенилметанона | |
UA102087C2 (en) | 3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6receptors, methods for the production and the use thereof | |
AR079509A1 (es) | Tiazoles biciclicos como moduladores alostericos de receptores mglur5 | |
MX2016014845A (es) | Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona. | |
EA201291281A1 (ru) | Производные хинолизидина и индолизидина | |
TH171910A (th) | เปบไทด์ที่เป็นออกซีโทซินอะโกนิสต์ | |
EA201291374A1 (ru) | Производные амидотропана | |
TH167739B (th) | เปปไทด์เป็นตัวทำการออกซีโทซิน | |
TN2013000345A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2703 DE 25/10/2022. |